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Abstract
The apolipoprotein E (APOE) gene may act differently in young and old persons, known as antagonistic pleiotropy. We therefore
examined the prospective associations between the APOE 4 allele and cognitive functioning, and the modifying effect of age, in 375
ondemented adults (mean age 57  10 years; follow-up period 3.8  0.2 years) with available data on APOE genotype and cognitive
functioning, within the SMART-MR (Second Manifestations of ARTerial disease-Magnetic Resonance) cohort study. Neuropsychological
tests assessing memory performance and executive functioning were performed at baseline and follow-up, and composite z-scores were
calculated. Age significantly modified the association of APOE 4 with change in memory performance (p interaction  0.02). In persons
57 years (median split), an APOE 4 allele was associated with an increase in immediate recall (B  0.42; 95% confidence interval [CI],
.17 to 0.66) and delayed recall (B  0.37; 95% CI, 0.09 to 0.64), while in persons  57 years, an APOE 4 allele was associated with
ecline in immediate recall (B  0.25; 95% CI, 0.52 to 0.01). Our findings suggest that the APOE 4 allele has a differential effect on
hange in verbal memory performance depending on age, consistent with the hypothesis of antagonistic pleiotropy.
2012 Elsevier Inc.
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The apolipoprotein E (APOE) 4 allele is a well
known genetic risk factor for Alzheimer’s disease (AD)
(Farrer et al., 1997). However, some studies indicate that
the APOE 4 allele might have a beneficial effect on
cognitive performance at younger age (Alexander et al.,
2007; Mondadori et al., 2007; Wright et al., 2003). It
could therefore be an example of antagonistic pleiotropy
(Schultz et al., 2008), which means that a gene may have
beneficial effects at younger age, but deleterious effects
later in life (Albin, 1993).
Numerous longitudinal studies in older, cognitively
impaired people showed that possession of an APOE 4
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Open access under the Elsevier OA license.allele is associated with cognitive decline (Dik et al.,
2000; Farlow et al., 2004) and an increased risk to de-
velop AD (Bondi et al., 1999; Corder et al., 1993). In
cognitively healthy older people, the effect of the APOE
4 allele on cognitive functioning is less consistent, with
some studies showing no association and others showing
a worse performance in APOE 4 carriers (Bunce et al.,
2004; Caselli et al., 2009; Honea et al., 2009; Kim et al.,
2002; Small et al., 2004). Moreover, some studies in
young adults and children have found evidence of better
cognitive performance in APOE 4 carriers (Alexander et
al., 2007; Mondadori et al., 2007; Wright et al., 2003)
although these studies are few and some also found no
association (Bloss et al., 2008; Deary et al., 2002). How-
ever, prospective data on the association of APOE 4
with cognitive decline in a population with a wide age
range are scarce (Kozauer et al., 2008).
To further investigate this phenomenon of antagonistic
pleiotropy, the objective of this study was to examine the
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cognitive functioning in a cohort of nondemented adults
with a wide age range, and to examine the modifying effect
of age in this relationship. We hypothesized that APOE 4
was associated with better cognitive functioning over time
in younger subjects, and with worse cognitive functioning
in older subjects.
2. Methods
2.1. SMART-MR study
Data were used from the SMART-MR (Second Manifes-
tations of ARTerial disease-Magnetic Resonance) study, a
prospective cohort study aimed to investigate brain changes
on magnetic resonance imaging (MRI) in 1309 indepen-
dently living persons with symptomatic atherosclerotic dis-
ease (Geerlings et al., 2010; Muller et al., 2011). In brief,
between May 2001 and December 2005, all persons newly
referred to the University Medical Center Utrecht (UMCU)
with manifest coronary artery disease, cerebrovascular dis-
ease, peripheral arterial disease, or an abdominal aortic
aneurysm, and without magnetic resonance (MR) contrain-
dications were invited to participate. Coronary artery dis-
ease was defined as myocardial infarction, coronary artery
bypass graft surgery or percutaneous transluminal coronary
angioplasty in the past or at inclusion. Patients with a
transient ischemic attack or stroke at inclusion and patients
who reported stroke in the past were considered to have
cerebrovascular disease. Peripheral arterial disease was de-
fined as surgery or angioplasty of the arteries supplying the
lower extremities in history or intermittent claudication or
rest pain at inclusion. Abdominal aortic aneurysm (AAA)
was defined as present AAA (distal aortic diameter  3 cm)
or previous AAA surgery. During a 1-day visit to our
medical center, an MRI of the brain was performed, in
addition to a physical examination, ultrasonography of the
carotid arteries, and blood and urine sampling. Risk factors,
medical history, and functioning were assessed with ques-
tionnaires that the persons completed before their visit to the
medical center. Neuropsychological testing was introduced
in the SMART-MR study starting in January 2003 and was
performed on the same day as the MRI and other investi-
gations, and was available in 831 of the 1309 persons.
Between January 2006 and May 2009, all participants still
alive were invited for follow-up measurements.
The SMART-MR study was approved by the ethics com-
mittee of the UMCU and written informed consent was
obtained from all participants.
2.2. Study sample
Of the 831 persons, APOE genotyping was performed in
all persons included between January 2003 and April 2005
(n  671). Of these, 378 (59% of the persons still alive)
articipated in the follow-up examination. Three persons vith dementia (see below) were excluded. As a result, the
rospective analyses were performed in 375 persons.
Compared with these 375 persons, the 296 persons ex-
luded from the present analyses were, at study entry, on
verage older (mean age [SD]: 60 [10] vs. 57 [10] years;
 0.001), more often female (26% vs. 20%; p  0.041),
ad higher systolic and diastolic blood pressure levels (re-
pectively 149 [25] vs. 142 [20] mm Hg; p  0.001; and 85
12] vs. 83 [11] mm Hg; p  0.021), more often had
yperlipidemia (82% vs. 75%; p  0.021) and diabetes
ellitus (24% vs. 14%; p  0.001), had poorer global
ognitive performance (z-score global cognitive function-
ng: 0.29 [1.08] vs. 0.19 [0.87]; p  0.001), and were
omewhat more often APOE 4 carriers, although not sta-
istically significant (37% vs. 31%; p  0.076).
.3. APOE genotype
DNA was isolated from 10 mL of ethylenediaminetet-
aacetic acid (EDTA) (citrate)-augmented blood stored at
80 °C, and amplified with polymerase chain reaction
PCR). To determine the APOE genotype (APOE 2, 3,
nd 4 alleles) 2 single-nucleotide polymorphisms (SNPs:
ational Center for Biotechnology Information (NCBI)
NPs rs7412 and rs429358) were genotyped. Genotyping
as performed with the 5= nuclease/Taqman assay (Applied
iosystems, Foster City, CA, USA) (Livak, 1999). Poly-
erase chain reactions with fluorescent allele-specific oli-
onucleotide probes (Applied Biosystems, Foster City, CA,
SA) were performed on a PTC-225 thermal cycler
Biozym, Hessisch Oldendorf, Germany), and fluorescence
nd point reading for allelic discrimination was performed
n an ABI 7900 HT (Applied Biosystems 7900 high-
hroughput). Genotyping for APOE was performed on
oded DNA specimens without knowledge of the diagnosis.
.4. Cognition and dementia
Cognitive functioning was assessed with a set of stan-
ard neuropsychological tests, sensitive to mild impair-
ents. Verbal memory was assessed with the 15-word
earning test, a modification of the Rey Auditory Verbal
earning test (Brand and Jolles, 1985). In 5 consecutive
rials immediate recall was assessed and after 20 minutes
elayed recall was assessed. Visual memory was assessed
ith the Rey-Osterrieth Complex Figure delayed recall
est in which the recall of a complex figure, copied 30
inutes before, is requested (Rey, 1941). A composite
core for memory performance at baseline was calculated
y averaging the z-scores (individual test score minus
ean test score divided by the standard deviation of that
core) for the mean score of the 5 trials of the immediate
ecall, the z-score for the delayed recall, and the z-score
or the Rey-Osterrieth Complex Figure delayed recall
est. A composite score for memory performance at fol-
ow-up was calculated by averaging the z-scores (indi-
idual follow-up test score minus mean baseline test
ms
c
d
t
w
d
2
d
m
i
m
a
y
c
b
w
P
a
i
s
p
p
o
p
e
2
s
a
w
t
a
c
c
f
p
y
b
a
c
z
s
t
t
a
w
s
s
r
t
p
t
D
c
a
(
c
p
832.e17H.M. Jochemsen et al. / Neurobiology of Aging 33 (2012) 832.e15–832.e22score divided by the standard deviation of the baseline
test score) for the 3 memory tests.
Executive functioning was assessed with 3 tests. The
Visual Elevator Test, a subtest of the Test of Everyday
Attention, is a timed test of 10 trials that measure mental
flexibility and shifting of attention (Robertson et al., 1994).
The timing score of the Visual Elevator test is equivalent to
time per switch for correct items (seconds per switch). The
Brixton Spatial Anticipation test was used to assess the
capacity to discover logical rules and mental inhibition and
flexibility. The total number of errors made was scored
(Burgess and Shallice, 1996). The letter Verbal Fluency test
(letter N at baseline and A at follow-up) was used in a
1-minute time frame to assess mental flexibility and em-
ployment of strategies (Lezak, 1995). Before calculating the
z-score, the scores of the Visual Elevator test and Brixton
Spatial Anticipation test were multiplied by 1, so that
lower scores represented poorer performance. The compos-
ite score for executive functioning at baseline was calcu-
lated by averaging the z-score (individual test score minus
ean test score divided by the standard deviation of that
core) for the Visual Elevator test—timing score, the z-score
for the Brixton Anticipation test, and the z-score for the
letter Verbal Fluency test. A composite score for execu-
tive functioning at follow-up was calculated by averaging
the z-scores (individual follow-up test score minus mean
baseline test score divided by the standard deviation of the
baseline test score) for the 3 executive functioning tests.
General cognitive functioning at follow-up was assessed
with the Mini Mental State Examination (MMSE), and
participants with a score  27 were examined by a physi-
ian who conducted an additional in-house standardized
ementia interview and physical examination. These results,
ogether with the outcome of the neuropsychological testing
ere discussed in a consensus meeting with a geriatrician to
iagnose dementia.
.5. Covariates
An overnight fasting venous blood sample was taken to
etermine glucose and lipid levels. Height and weight were
easured without shoes and heavy clothing, and body mass
ndex was calculated (weight [kg]/height [m2]). Systolic and
diastolic blood pressure (mm Hg) were measured twice in
sitting position with a sphygmomanometer, and the average
was obtained. Diabetes mellitus was defined as a glucose
level of  7.0 mmol/L or use of oral antidiabetic drugs or
insulin. Hyperlipidemia was defined as total cholesterol 
5.0 mmol/L, low-density lipoprotein cholesterol  3.2
mol/L or use of lipid lowering drugs. Smoking habits and
lcohol intake were assessed by using questionnaires. Pack-
ears of smoking were calculated as the average number of
igarettes smoked per day divided by 20 and then multiplied
y the number of years of cigarette smoking. Alcohol intake
as divided into 3 categories: never, former, and current.
ersons who had quit drinking during the past year weressigned to the category current alcohol intake. Premorbid
ntellectual functioning was assessed using the Dutch ver-
ion of the National Adult Reading Test (DART) in which
ersons had to read out loud a list of words with irregular
ronunciation (Schmand et al., 1998). Highest attained level
f education was assessed with 7 categories, graded from
rimary school to academic degree, according to the Dutch
ducational system.
.6. Data analysis
First, baseline characteristics were calculated for the total
tudy population and for APOE 4 categories (1 or 2 4
lleles vs. no 4 allele). Second, linear regression analysis
as used to investigate the prospective associations be-
ween APOE genotype (1 or 2 4 alleles vs. no 4 allele)
nd change in measures of cognitive functioning by using
ognitive z-scores at follow-up as dependent variable and
ognitive z-scores at baseline as independent variable.
We adjusted for age, sex, education, the DART score,
ollow-up time, systolic and diastolic blood pressure, hy-
erlipidemia, diabetes mellitus, body mass index, pack-
ears of smoking, and alcohol intake.
To assess the modifying effect of age on the relation
etween APOE 4 and change in cognitive function, we
dded interaction terms between APOE 4 and age (as a
ontinuous variable) with the z-score of memory and the
-score of executive functioning. If the interaction term was
tatistically significant (p  0.05), we repeated the interac-
ion terms with the z-scores for the individual cognitive
ests. If the regression analyses revealed a significant inter-
ction between APOE 4 and age, we associated APOE 4
ith change in cognitive functioning (z-scores and crude
cores for the individual tests) within strata of age (median
plit: age  57 and  57 years old).
Furthermore, predicted values for change in immediate
ecall and delayed recall (crude scores for the individual
ests: number of words) for carriers and noncarriers were
lotted with a regression model including age, APOE 4,
he interaction between age and APOE 4, sex, education,
ART score, and vascular risk factors.
Because the 2 allele might have a beneficial effect on
ognitive function (Blacker et al., 2007), we repeated the
nalyses after exclusion of persons with 24 genotype
n  7). Finally, because some persons may have impaired
ognition, the analyses were repeated after exclusion of
ersons with an MMSE  27 (n  15). Because missing
data on covariates were few (n  27) we performed com-
plete case analysis. In all analyses, we report 95% confi-
dence intervals (CI). The statistical package SPSS version
17.0 (Chicago, IL, USA) was used to analyze the data.
3. Results
At baseline, the mean (SD, range) age of the study
population was 57 (10, 27–79), 80% was male, and 31%
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f which 92% (n  107) had 1 APOE 4 allele and 8%
(n  9) had 2 APOE 4 alleles.
Table 1 shows the baseline characteristics of the study
sample according to APOE 4 allele status. APOE 4 car-
riers had a somewhat higher risk of nonparticipation in the
follow-up examination; the crude odds ratio OR (95% CI)
was 1.28 (0.93 to 1.77), and the age-adjusted odds ratio
(95% CI) was 1.33 (0.96 to 1.84).
After a mean (SD, range) follow-up period of 3.8 (0.2,
3.3– 4.6) years, APOE 4 was not associated with a
hange in memory performance or executive functioning;
(95% CI) were 0.05 (0.07 to 0.18) and 0.04 (0.09
o 0.01), respectively. When an interaction term between
POE 4 and age was added to the model, we found that
ge significantly modified the association of APOE 4
ith a change in z-score of memory performance (p
nteraction  0.02).
When looking at the individual memory tests, age sig-
ificantly modified the association of APOE 4 with change
n z-score for immediate and delayed recall (p interaction 
0.01 and 0.04), but not with change in z-score for visual
memory (p  0.91) (Table 2). Furthermore, age did not
odify the association between APOE 4 and change in
-score of executive functioning (p interaction  0.55).
Table 1
Baseline characteristics for categories of APOE 4 genotype and the total
Characteristics No APOE 4
allele (n  259)
Agea 58  10
Male gender, n (%) 209 (81)
Educationb 4 (1, 6)
ART scoreb 82 (56, 97)
yperlipidemia, n (%) 191 (75)
Diabetes mellitus, n (%) 35 (14)
Systolic blood pressure (mm Hg)a 143  20
Diastolic blood pressure (mm Hg)a 84  11
Body mass index, kg/m2a 27  3
Smoking (pack-years)b 16 (0, 48)
urrent alcohol use, n (%) 201 (78)
Key: APOE, apolipoprotein E; DART, Dutch version of the national Adu
a Mean  SD.
b Median (10th, 90th percentile).
Table 2
Regression coefficients of the interaction between APOE 4 genotype and
scores of individual tests) after 3.8 years of follow-up
Change in memory performance (z-scores)
Memory performance
B (95% CI)a
Verbal imme
B (95% CI)a
APOE 4 allele 0.10 (0.07 to 0.21) 0.10 (0.0
Age 0.01 (0.02 to 0.00) 0.02 (0.0
APOE 4  age 0.02 (0.04 to 0.00) 0.03 (0.0
p interaction 0.022 0.007
Key: APOE, apolipoprotein E; CI, confidence interval; DART, Dutch ver
a Adjusted for sex, education, the DART score, follow-up time, baselinemellitus, body mass index, pack-years of smoking and alcohol intake.Table 3 presents the results of the association of APOE
4 with change in memory performance across strata of age
median split: age  57 and  57 years). In persons  57
years (n 188), APOE 4 was associated with a significant
increase in global memory performance and in immediate
and delayed verbal recall, after adjusting for age, sex, edu-
cation, DART score, follow-up time, and vascular risk fac-
tors. However, in persons  57 years (n  187), APOE 4
was associated with a decrease in global memory perfor-
mance, immediate and delayed verbal recall (Table 3).
Fig. 1 shows the predicted values for change in imme-
diate recall and delayed recall (number of words) for carri-
ers and noncarriers, adjusted for age, APOE 4, the inter-
action between age and APOE 4, sex, education, DART
score, and vascular risk factors (Fig. 1A and B). These
figures show that APOE 4 noncarriers do not considerably
change in verbal memory performance during the follow-up
period, whereas APOE 4 carriers show an improvement of
verbal memory compared with noncarriers before their late
fifties, and a decline in verbal memory at later age. For
instance, at age 40 years APOE 4 carriers have a predicted
improvement of about 6 words on immediate recall at fol-
low-up, whereas noncarriers show hardly any improvement.
On the contrary, at age 75 years APOE 4 carriers show a
tion
1 or 2 APOE 4
alleles (n  116)
Total population
(n  375)
56  9 57  10
92 (79) 301 (80)
3 (2, 6) 3 (2, 6)
80 (63, 97) 82 (58, 97)
87 (75) 278 (75)
18 (16) 53 (14)
140  20 142  20
81  11 83  11
26  3 27  3
20 (0, 46) 19 (0, 48)
89 (77) 290 (78)
ing Test (range 0–100).
relation to change in memory performance (composite z-score and z-
call Verbal delayed recall
B (95% CI)a
Visual delayed recall
B (95% CI)a
8) 0.14 (0.05 to 0.33) 0.03 (0.13 to 0.19)
.01) 0.02 (0.03 to 0.01) 0.01 (0.02 to 0.00)
.01) 0.02 (0.04 to 0.00) 0.00 (0.02 to 0.02)
0.038 0.906
the national Adult Reading Test.
ive z-score, systolic and diastolic blood pressure, hyperlipidemia, diabetespopula
lt Readage in
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8 to 0.2
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follow-up, whereas noncarriers show no decline.
Analyses were repeated with exclusion of 24 carri-
ers (n  7), but the results did not change (data not
shown). Finally, after exclusion of potentially cognitively
impaired persons (MMSE  27, n  15), the results in
persons  57 years did not change (data not shown),
whereas in persons  57 the association with APOE 4
and decline in the z-score for immediate verbal recall
became slightly stronger (B  0.29; 95% CI, 0.58 to
0.01; p  0.041).
4. Discussion
In a nondemented population with symptomatic athero-
sclerotic disease we observed that possession of the APOE
4 allele was associated with verbal memory improvement
during 4 years of follow-up in persons  57 years, whereas
in persons  57 years the APOE 4 allele was associated
with a verbal memory decline. These associations were
independent of demographics and cardiovascular risk fac-
tors.
To date, an increasing number of studies suggest a ben-
eficial role of the APOE 4 allele in younger age on cog-
nition (Mondadori et al., 2007; Wright et al., 2003), educa-
tional achievement (Hubacek et al., 2001), and IQ (Yu et al.,
2000), whereas the well-documented negative conse-
quences of possessing an 4 allele, including greater risk for
developing dementia and poorer cognitive aging, may not
emerge until after the fifth decade of life (Caselli et al.,
2009). This has led to the hypothesis that the APOE gene
may be an example of antagonistic pleiotropy (Han and
Bondi, 2008). The differential effects of APOE 4 in
younger and older subjects that we observed in this study
Table 3
Association of the APOE 4 allele with change in memory performance (
individual tests) after 3.8 years of follow-up within strata of age
Change in memory performance according to age groups
Z-score memory performance B (95% CI) Z-score verb
 57 y (n  188)  57 y (n  187)  57 y (n 
APOE 4
allelea
0.34 (0.09 to 0.59) 0.16 (0.40 to 0.08) 0.42 (0.17 to
value 0.008 0.193 0.001
Crude score
B (95% CI)
 57 y (n 
POE 4
alleleb
3.96 (1.60 to
value 0.001
djusted for age, sex, education, the DART-score, follow-up time, baseline
ellitus, body mass index, pack-years of smoking and alcohol intake.
ey: APOE, apolipoprotein E; CI, confidence interval; DART, Dutch ver
a Regression coefficients represents the adjusted mean difference in z-s
b Regression coefficients represents the adjusted mean difference in abare in line with this concept. (Although the mechanisms causing the beneficial effect
on cognition of APOE 4 in younger age are unclear, it
could be hypothesized that this is due to its role in choles-
terol metabolism, an underlying contributing mechanism for
neurite outgrowth and synaptogenesis, which are processes
that are critical to neurodevelopment (Bothwell and Gini-
ger, 2000; Herz and Beffert, 2000). The mechanisms caus-
ing the deleterious effect at older age are also still unclear,
but the effect of APOE 4 on episodic memory is thought to
be mediated by hippocampal atrophy (Small et al., 2004),
while the general cognitive effects of APOE 4 might be
related to its link with -amyloid plaques and neurofibril-
ary tangles (Warzok et al., 1998), the hallmark neuropatho-
ogic characteristics of AD.
We found that APOE 4 in nondemented older persons
as associated with immediate verbal memory decline, but
ot with decline in visual memory or executive functioning.
emory performance as assessed with the 15-word learning
est is mainly a function of the hippocampus (O’Brien et al.,
003). Furthermore, memory impairment is most commonly
he earliest cognitive symptom of Alzheimer’s dementia.
his is in line with our study that shows that memory
ecline, possibly as a result of the role of APOE 4 on
ippocampus atrophy, can already be seen in nondemented
ersons. Yet, whereas most studies in older nondemented
ersons reported statistically significant cognitive decline
ith APOE4, we found a smaller decline than shown in
ost studies, and it was not statistically significant, al-
hough the interaction between age and APOE was highly
ignificant. An explanation might be that the subgroup of
lder persons was based on a median split of our study
ample at 57 years, while most studies finding a significant
ecline were performed in persons older than 65 years
site z-scores, z-scores of the individual tests and crude scores of the
ediate recall B (95% CI) Z-score verbal delayed recall B (95% CI)
 57 y (n  187)  57 y (n  188)  57 y (n  187)
0.25 (0.52 to 0.01) 0.37 (0.09 to 0.64) 0.09 (0.35 to 0.17)
0.060 0.010 0.493
immediate recall Crude score verbal delayed recall
B (95% CI)
 57 y (n  187)  57 y (n  188)  57 y (n  187)
2.42 (4.94 to 0.10) 1.08 (0.27 to 1.90) 0.27 (1.04 to 0.51)
0.060 0.010 0.493
ive z-score, systolic and diastolic blood pressure, hyperlipidemia, diabetes
the national Adult Reading Test.
tween 4 carriers and noncarriers.
umber of words recalled between 4 carriers and noncarriers.compo
al imm
188)
0.66)
verbal
188)
6.31)
cognit
sion of
core beBretsky et al., 2003; Bunce et al., 2004; Jonker et al.,
m2
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late fifties the function of the APOE 4 allele on verbal
memory may change, it is possible that some of the persons
in the older age group did not yet experience the negative
effect of APOE 4.
In our study the younger persons demonstrated a verbal
memory improvement, which might indicate a protective
role of APOE 4 on the mechanisms underlying verbal
memory impairment, such as hippocampus atrophy. The
few studies that examined the role of APOE 4 in cogni-
tively healthy persons in 2 or more age groups reported
inconsistent results. Some studies showed that younger sub-
jects with the APOE 4 allele had better cognitive perfor-
ance (Baxter et al., 2003; Liu et al., 2010; Schultz et al.,
008), whereas other studies found no association (Jorm et
l., 2007) or even a decline in cognitive performance in
oung 4 carriers (Kozauer et al., 2008). The reasons for
hese inconsistent findings may be the short follow-up pe-
Fig. 1. Predicted values of immediate and delayed recall according to age,
for carriers and noncarriers. (A) Predicted values of change in immediate
recall (number of words) during follow-up for carriers and noncarriers,
adjusted for age, apolipoprotein E (APOE) 4, the interaction between age
and APOE 4, sex, education, the Dutch version of the National Adult
Reading Test (DART) score and vascular risk factors. (B) Predicted values
of change in delayed recall (number of words) during follow-up for carriers
and noncarriers, adjusted for age, APOE 4, the interaction between age
and APOE 4, sex, education, the DART score, and vascular risk factors.iod (Baxter et al., 2003) or the cross-sectional design ofsome studies (Jorm et al., 2007; Liu et al., 2010). The study
that showed a decline in young 4 carriers, had a very long
follow-up period (22 years), and it is possible that the
inversion point was missed (Kozauer et al., 2008). Prospec-
tive studies in populations with a wide age range, a long
follow-up period, and several interim measurements are
needed to reliably assess the association between APOE 4
and cognition across the lifespan.
Strengths of our study include the prospective design and
the wide age range of the sample, which facilitated the aim
to associate APOE 4 with a change in cognitive perfor-
mance across a wide age range, to examine the concept of
antagonistic pleiotropy. A potential limitation is that the
patients who participated in the follow-up examination
might represent a healthier group due to, for example, se-
lective mortality or morbidity. Although the age-adjusted
association between APOE 4 and nonparticipation was not
statistically significant, it is thus possible that the memory
improvement in the younger group is somewhat overesti-
mated, while the memory decline in the older group may
have been underestimated. Furthermore, persons with 2 4
alleles are more vulnerable for Alzheimer’s disease than
persons with 1 4 allele (Corder et al., 1993), and the
detrimental effect of APOE 4 on memory decline may start
at an earlier age in persons with 2 4 alleles than those with
1 4 allele (Liu et al., 2010). Unfortunately, we could not
reliably analyze these groups separately because there were
only 9 persons with 2 4 alleles in our study. Finally, our
study sample consisted of persons with symptomatic ath-
erosclerotic disease and the majority were male, and our
results could therefore not be fully applicable to the general
population. However, as the relations were largely indepen-
dent of the presence of vascular risk factors such as blood
pressure and hyperlipidemia, we could argue that the results
may also apply for the general population.
In summary, in a nondemented population with symp-
tomatic atherosclerotic disease, possession of an APOE 4
allele was associated with memory improvement during 4
years of follow-up in younger individuals, whereas in older
individuals the APOE 4 allele was associated with memory
decline. Consistent with the phenomenon of antagonistic
pleiotropy, these findings might indicate a differential effect
of the 4 allele on memory performance, with a change in
function after the late fifties. Identification of possible en-
vironmental or genetic factors interacting with the APOE 4
allele might give new targets for medication to influence the
development of Alzheimer’s dementia.
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